Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146099 | 0.82 | CES1 (0.43) | TDP1L3MBTL1ATMHDAC8HDAC6 | |
| SCHEMBL2909086 | 0.78 | MAPT (0.35) | HSD17B10 | |
| SCHEMBL22121818 | 0.76 | CES2 (0.55) | TDP1HDAC8CA1CA2CES2 | |
| SCHEMBL9451857 | 0.72 | ALDH1A1 (0.53) | TDP1ATMHDAC6KMT2AGAA | |
| SCHEMBL10452133 | 0.69 | TSHR (0.58) | CA12CA1CA2CA6CA9 | |
| SCHEMBL334045 | 0.68 | NAPRT (0.46) | L3MBTL1CA1CA9KMT2AMEN1 | |
| SCHEMBL9554891 | 0.68 | CES2 (0.48) | L3MBTL1ATMCA1CA2CES2 | |
| SCHEMBL535862 | 0.65 | CES1 (0.48) | TDP1L3MBTL1ATMHDAC8HDAC6 | |
| SCHEMBL20494918 | 0.65 | TDP1 (0.40) | TDP1L3MBTL1ATMHDAC8HDAC6 | |
| SCHEMBL167439 | 0.65 | FURIN (0.43) | TDP1L3MBTL1ATMHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118349-A1 | BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY | ONCO-PHARMAKON INCORPORATED (US) | 2009-05-07 | — | — | US | claimed |
| US-20090118349-A1 | BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY | ONCO-PHARMAKON INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118349-A1 | BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY | UNG, MPG, DIMT1 | TDP1 430/4885L3MBTL1 796/4885ATM 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.